Longeveron® Announces Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024 16:05 ET
|
Longeveron
Longeveron reports Q2 2024 financial results and provides business update. Phase 2b clinical trial in HLHS achieves 70% enrollment.
Longeveron® to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024
August 05, 2024 16:05 ET
|
Longeveron
Longeveron announced that it will report Q2 2024 financial results and provide a business update on Wednesday, August 14, 2024.
Neha Motwani Elected to Longeveron® Board of Directors
July 09, 2024 09:00 ET
|
Longeveron
Neha Motwani, a senior healthcare investment banker, has been elected to the Longeveron Board of Directors
Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors
July 08, 2024 09:00 ET
|
Longeveron
Gene therapy pioneer Dr. Roger Hajjar elected to Longeveron Board of Directors as company advances it novel cellular therapy across multiple indications.
Longeveron® to Present at the Virtual Life Sciences Investor Forum on June 20, 2024
June 17, 2024 09:00 ET
|
Longeveron
Longeveron, a clinical stage biotechnology company developing cellular therapies, will present at the Virtual LIfe Sciences Investor Forum on June 20th.
Longeveron® Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B™ as a Potential Treatment for HLHS, a Rare Pediatric Cardiac Disease
June 11, 2024 09:00 ET
|
Longeveron
Investigator meeting for ELPIS II, the on-going Phase 2b clinical trial evaluating Lomecel-B as a potential adjunct treatment for HLHS.
Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024
June 10, 2024 09:00 ET
|
Longeveron
Longeveron to Present at the Emerging Growth Virtual Conference
Longeveron® Announces Contract Development and Manufacturing Business and First Contract
June 03, 2024 09:00 ET
|
Longeveron
Longeveron launches contract development and manufacturing business for stem cell therapies. 15,000 sf state-of-the-art GMP facility with 8 cleanrooms.
Longeveron Announces First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 16:05 ET
|
Longeveron
Longeveron announces 2024 Q1 financial results and business update. Phase 2b study in rare pediatric disease HLHS on track to complete enrollment in 2024.
Longeveron Announces Board of Directors Planned Transitions
May 10, 2024 16:05 ET
|
Longeveron
Longeveron announces planned transitions on its Board of Directors.